Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has been assigned an average recommendation of “Moderate Buy” from the twenty brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $165.63.

Several equities research analysts recently weighed in on the company. Piper Sandler dropped their target price on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Morgan Stanley dropped their price objective on Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Barclays lifted their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. UBS Group increased their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners raised their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th.

Hedge Funds Weigh In On Illumina

Institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC boosted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of Illumina during the second quarter valued at approximately $61,000. Finally, Private Trust Co. NA lifted its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.5 %

ILMN stock opened at $136.67 on Monday. The company has a market capitalization of $21.68 billion, a PE ratio of -13.72 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina has a one year low of $100.08 and a one year high of $156.66. The company’s 50 day moving average price is $139.60 and its two-hundred day moving average price is $133.57.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. The firm’s revenue was down 3.5% compared to the same quarter last year. As a group, analysts predict that Illumina will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.